{"id":3942,"date":"2018-04-15T08:13:00","date_gmt":"2018-04-15T08:13:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=3942"},"modified":"2024-05-02T11:28:40","modified_gmt":"2024-05-02T09:28:40","slug":"changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/","title":{"rendered":"Changes in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease"},"content":{"rendered":"
\n

Shingo Kato<\/a>,\u00a0Akira Ishibashi<\/a>,\u00a0Kaori Sugiura<\/a>,\u00a0Kazuhito Kani<\/a>,\u00a0Tomonari Ogawa<\/a>,\u00a0Hajime Hasegawa<\/a>,\u00a0Koji Yakabi<\/a>, Contrib Nephrol 2018;196:200-208.<\/p>\n<\/div>\n\n

\n

GMA decreases inflammatory cytokines and upregulates regulatory T cells. Intensive GMA is significantly more effective than weekly GMA in patients with IBD. The frequency of GMA sessions per week positively correlates with treatment effects. GMA can be safely used in pregnant women and children because of its low adverse event rates. Maintenance therapy and rescue therapy for loss of response of anti-tumor necrosis factor (TNF)-\u03b1 antibodies are effective. Optimal patients who responded to combination therapy with infliximab and GMA showed aggravation characteristics against infliximab treatment at week 4. Key Message: Prospective randomized blinded studies using a sham column should be performed for the loss of response against anti-TNF-\u03b1 antibodies.<\/p>\n<\/div>\n\n

\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/30041228\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Shingo Kato,\u00a0Akira Ishibashi,\u00a0Kaori Sugiura,\u00a0Kazuhito Kani,\u00a0Tomonari Ogawa,\u00a0Hajime Hasegawa,\u00a0Koji Yakabi, Contrib Nephrol 2018;196:200-208. GMA decreases inflammatory cytokines and upregulates regulatory T cells. Intensive GMA is significantly more effective than weekly GMA in patients with IBD. The frequency of GMA sessions per week positively correlates with treatment effects. GMA can be safely used in pregnant women and children […]<\/p>\n","protected":false},"template":"","scientific_tags":[92,147,159,79,312,91,313,72,156,311,90,306],"class_list":["post-3942","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-anti-tnf","scientific_tags-clinical-remission","scientific_tags-crohns-disease","scientific_tags-cytokines","scientific_tags-immunology","scientific_tags-maintenance","scientific_tags-pediatry","scientific_tags-pregnancy","scientific_tags-safety","scientific_tags-special-situations","scientific_tags-tregs","scientific_tags-ulcerative-colitis"],"acf":[],"yoast_head":"\nChanges in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changes in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Shingo Kato,\u00a0Akira Ishibashi,\u00a0Kaori Sugiura,\u00a0Kazuhito Kani,\u00a0Tomonari Ogawa,\u00a0Hajime Hasegawa,\u00a0Koji Yakabi, Contrib Nephrol 2018;196:200-208. GMA decreases inflammatory cytokines and upregulates regulatory T cells. Intensive GMA is significantly more effective than weekly GMA in patients with IBD. The frequency of GMA sessions per week positively correlates with treatment effects. GMA can be safely used in pregnant women and children […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T09:28:40+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/\",\"name\":\"Changes in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2018-04-15T08:13:00+00:00\",\"dateModified\":\"2024-05-02T09:28:40+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Changes in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"Changes in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease - Adacyte","og_description":"Shingo Kato,\u00a0Akira Ishibashi,\u00a0Kaori Sugiura,\u00a0Kazuhito Kani,\u00a0Tomonari Ogawa,\u00a0Hajime Hasegawa,\u00a0Koji Yakabi, Contrib Nephrol 2018;196:200-208. GMA decreases inflammatory cytokines and upregulates regulatory T cells. Intensive GMA is significantly more effective than weekly GMA in patients with IBD. The frequency of GMA sessions per week positively correlates with treatment effects. GMA can be safely used in pregnant women and children […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T09:28:40+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/","name":"Changes in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2018-04-15T08:13:00+00:00","dateModified":"2024-05-02T09:28:40+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/changes-in-treatment-with-granulocyte-and-monocyte-adsorptive-apheresis-from-the-past-to-future-in-patients-with-inflammatory-bowel-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/3942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=3942"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=3942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}